Michelon Francois Roger 4
4 · ENDRA Life Sciences Inc. · Filed Nov 15, 2018
Insider Transaction Report
Form 4
Michelon Francois Roger
DirectorChief Executive Officer
Transactions
- Conversion
Common Stock
2018-11-13$1.68/sh+5,953$10,001→ 32,497 total - Conversion
Convertible Promissory Note
2018-11-13$10000.00/shExercise: $1.68Exp: 2018-12-31→ Common Stock (5,953 underlying)
Footnotes (2)
- [F1]These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note described in footnote (2).
- [F2]Pursuant to the terms of the Convertible Promissory Note (the "Note"), the principal amount of the Note automatically converted into shares of the Issuer's Common Stock upon the consummation of a Qualified Financing (as defined in the Note) at the lowest per share price at which Common Stock was sold by the Issuer in the Qualified Financing, less a discount of 20%.